Relevant bibliographies by topics / 973.8/092 b

Academic literature on the topic '973.8/092 b'

Author: Grafiati
Published: 25 July 2024
Last updated: 31 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '973.8/092 b.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "973.8/092 b"

1

Kepert, Cameron J., Lu Wei-Min, Peter C. Junk, Brian W. Skelton, and Allan H. White. "Structural Systematics of Rare Earth Complexes. XI (‘Maximally’) Hydrated Rare Earth(III) Trifluoro- and Trichloro-acetates." Australian Journal of Chemistry 52, no. 6 (1999): 459. http://dx.doi.org/10.1071/ch98042.

Full text
Abstract:
Room-temperature single-crystal X-ray structure determinations carried out on ‘maximally’ hydrated rare earth(III) trifluoroacetates, Ln(tfa)3.x H2O, crystallized at room temperature, show the Ln = La, Ce adducts to be isomorphous and monoclinic, P 21/c, a ≈ 11·9, b ≈ 12·8, c ≈ 9·8 8 Å, β ≈ 103·7°, Z = 4; they are trihydrates. The Ln = Pr, Lu (and, implicitly, intermediate Ln) adducts are also monoclinic, P 21/c, Z = 4, and trihydrates, but of a different polymorph, with a ≈ 9·2, b 18·8, c ≈ 9·8 Å, β ≈ 114°. For the four determinations, conventional R values on |F| were 0·038, 0·032, 0·036, and 0·034 for No 2952, 4821, 4544, and 4092 independent ‘observed’ (I > 3σ(I)) diffractometer reflections respectively. The Ln = La, Ce adducts are two-dimensional polymers, the sheets parallel to the bc plane; the other systems are binuclear, the two metal atoms being linked by four bridging carboxylate O-tfa-O′ ligands. In both structural types, the metal atoms are eight-coordinate, but differ in the number of water molecules (2 cf. 3) in the O8 array. Extension of previous studies by single-crystal X-ray methods on the structural characterization of trivalent rare earth trichloroacetates, ‘maximally’ hydrated at local ambience, Ln(tca)3.x H2O, suggests the following arrays to be prevalent. The Ln = La adduct is a pentahydrate, monoclinic, P21/c, a 5·636(7), b 22·454(4), c 16·58(1) Å, β 90·52(8)°, Z = 4 f.u., R 0·035 for No 4154. The compound is a linear polymer along a, successive nine-coordinate La (separated by a) being linked by three O-tca-O′ bridging ligands at the opposite faces of a tricapped trigonal prismatic array, the equatorial sites being filled by water molecules. The Ln = Ce adduct is a trihydrate, monoclinic, P 21/c, a 10·071(2), b 22·973(2), c 20·222(5) Å, b 119·48(2)°, Z= 8 f.u., R 0·050 for No 5019. The array is also linear polymeric, but with successive Ce being linked alternately now by sets of two and then four O-tca-O′ bridging carboxylates along b, the Ln = Ce coordination number being diminished (relative to La) to eight with the coordination of two water molecules to each metal. Ln = Pr, Lu (and, presumptively, intermediate Ln) are dihydrates, triclinic, P 1, a ≈ 11·70, b ≈ 12·8, c ≈ 15·3 Å, α ≈ 71, β ≈ 77·85, γ ≈ 65·5°, Z = 4 f.u., R 0·056, 0·059 for No 5650, 5398. The array is a linear polymer, similar to that of the Ln = Ce adduct but alongside the bridging acetate pair one of the water molecules now bridges, resulting in a stepped Ln 1 array (along c) rather than a quasi-straight one as is found for the Ln = Ce (and La) adduct. Structure determinations are also recorded for rare earth(III) trichloroacetate ethanol trisolvates, Ln(tca)3.3EtOH. Adducts of Ln = La, Yb (and, implicitly, intermediate Ln) are isomorphous, triclinic, P 1, a ≈ 12, b ≈ 11·8, c ≈ 11·4 Å, α ≈ 114, β ≈ 100, γ ≈ 104°, Z = 2 f.u., R 0·056, 0·050 for No 3843, 4171. The complexes are centrosymmetric dimers [(EtOH)3(tca-O)Ln(O-tca-O′)4Ln(O-tca)(HOEt)3], the two metal atoms being linked by four O-tca-O′ bridging carboxylate groups; the metal atoms are eight-coordinate, the other four sites being occupied by four oxygen atoms from unidentate ethanol and carboxylate moieties. Bis(bis(2-pyridyl)aminium) bis(diaquatetrakis(trichloroacetato)lanthanate(III)), 2(dpaH+) [(H2O)2-(tca-O)(tca-O,O′)2La(O-tca-O′)2La(O,O′-tca)2(O-tca)(OH2)2]2-, is triclinic, P 1, a, 13·901(2), b 13·764(3), c 10·073(2) Å, α 104·04(2), β 108·93(2), γ 101·50(2)°, Z = 1 binuclear f.u., R 0·045 for No 4999. The anion is binuclear, the two nine-coordinate lanthanum atoms being linked by a pair of bridging O-carboxylate-O′ groups. The other seven sites of the LaO9 array are occupied by a pair of O,O′ -chelating and one O-unidentate carboxylate groups and a pair of water molecules.
APA, Harvard, Vancouver, ISO, and other styles
2

FU, CHIH-CHIANG, JASON SHIAN-CHING JANG, I.-SUI LEE, and HUEI-SEN WANG. "STRAIN RATE DEPENDENCE ON THE HIGH TEMPERATURE MECHANICAL BEHAVIOR OF THE NI-18SI-3.0NB-1.0CR-0.2B INTERMETALLIC ALLOY." International Journal of Modern Physics B 23, no. 06n07 (March 20, 2009): 1040–46. http://dx.doi.org/10.1142/s0217979209060439.

Full text
Abstract:
The effect of strain rate and temperature on the mechanical behavior of the Ni -18 Si -3.0 Nb -1.0 Cr -0.2 B alloy was investigated by atmosphere-controlled tensile testing in vacuum and air atmosphere at different strain rates and different temperatures. The results reveal that the Ni -18 Si -3.0 Nb -1.0 Cr -0.2 B alloy exhibits ductile mechanical behavior (UTS > 1200 MPa, ε > 8%) at room temperature under different atmosphere conditions. In addition, both of the ultimate tensile strength and elongation exhibit quite insensitive response with respect to the loading strain rate when tests are held at temperatures below 973K. The elongation of the samples tested in vacuum and air for the Ni -18 Si -3 Nb -1 Cr -0.2 B alloy exhibits a significantly increase with temperature from 973K to 1073K. In addition, all fracture surfaces tested at 1073K in vacuum and air atmosphere presents a typical ductile fracture surface, a fully dimpled fracture pattern. The fact of increasing in elongation at high temperature (1073K) is suggested to be attributed by the dynamic recrystallization that occurs preferentially around the dispersion phase or grain boundaries and so as to enhance the ductility by reducing the stress concentration at or near grain boundaries.
APA, Harvard, Vancouver, ISO, and other styles
3

Harb, Wael, Mansoor N. Saleh, Kyriakos P. Papadopoulos, Feng Chai, Maria Larmar, Giovanni Abbadessa, Brian Schwartz, and Anthony Tolcher. "Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor." Blood 126, no. 23 (December 3, 2015): 5116. http://dx.doi.org/10.1182/blood.v126.23.5116.5116.

Full text
Abstract:
Abstract Background: ARQ 092 is an oral allosteric, potent and selective AKT inhibitor with in vitro and in vivo activity in solid and hematological tumors. ARQ 092-101, the first clinical trial of ARQ 092, has enrolled more than 100 subjects with advanced solid tumors or recurrent malignant lymphoma. As reported previously, the dose escalation portion of the study has been completed and two dosing schedules (intermittent and weekly), are recommended for phase 2 studies. The recommended phase 2 dose (RP2D) for the intermittent dosing schedule is 200 mg once daily (QD) (one week on, one week off) and for the weekly dosing schedule is 300 mg twice daily (BID) (one day on, six days off). [1, 2] Enrollment in an expansion cohort at RP2Ds is ongoing. Here we report the results from 11 subjects with lymphoma/CLL. Material and Methods: Subjects with lymphoma/CLL have been enrolled and treated in the dose escalation and expansion cohorts with intermittent or weekly dosing schedule at the RP2Ds. Tumor responses for subjects with lymphoma were evaluated based on the Revised Response Criteria for Malignant Lymphoma. Adverse events were evaluated based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Blood samples were collected for PK analysis. Archival or biopsy tumor tissue samples were collected for genetic analysis. Results: As of 15 Jun 2015, 11 subjects with lymphoma/CLL (73% male; median age 78 years; 5 follicular, 3 mantle cell, 2 diffuse large B cell, 1 CLL; 4 in dose escalation cohorts, 7 in expansion cohort) have been enrolled and treated at initial doses of 120 to 270 mg QD intermittently (n=7) or 300 mg BID weekly (n=4). All subjects have received at least one prior systemic therapy (median 2, range 1-6). Median duration on study treatment for all 11 subjects was 8 weeks (range 1 to 30 weeks). One subject with CLL and two with follicular lymphoma experienced durable partial responses, respectively with times to response of 8, 8 and 24 weeks and response durations of 16, 8+, and 2+ weeks. The two follicular PR subjects, one of whom had an AKT1 (E17K) mutation, remain on study treatment. In addition, one subject with follicular and one with mantle cell lymphoma experienced stable diseases. Four subjects experienced progressive diseases and two were not evaluable for tumor responses due to early consent withdrawal and clinical disease progression. Table 1. Common drug-related adverse events (≥10%) included macula-papular rash 45%, hyperglycemia 36%, mucosal inflammation 18% and stomatitis 18%. Response Follicular N=5 CLL N=1 Mantle cell N=3 Diffuse large B cell N=2 Total N=11 PR 2 1 3 SD 1 1 2 PD 1 2 1 4 NE 1 1 2 ORR 40% 100% 0% 0% 27% DCR 60% 100% 33% 0% 45% Conclusions: The safety profile of lymphoma subjects is consistent with subjects with solid tumors enrolled in this study. Preliminary signs of single agent activity have been documented with 3 PRs in heavily pretreated lymphoma/CLL including one with AKT1 (E17K) mutation. [1] First-in-human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumors cohorts. M. Saleh et al., Abstract LB-197, AACR 104th Annual Meeting, 6-10 Apr 2013. Washington, D.C. U.S. [2] First-in-human study with ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma. M. Saleh et al., Abstract 320, EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics , 18-21 Nov 2014, Barcelona, Spain Disclosures Harb: Onyx Pharmaceuticals: Consultancy. Chai:ArQule, Inc.: Employment. Larmar:ArQule, Inc.: Employment. Abbadessa:ArQule, Inc.: Employment. Schwartz:ArQule, Inc.: Employment.
APA, Harvard, Vancouver, ISO, and other styles
4

Hönle, Wolfgang, Sigrid Furuseth, and Hans Georg von Schnering. "Synthesis and Crystal Structure of Ordered, Orthorhombic α-NbBr5." Zeitschrift für Naturforschung B 45, no. 7 (July 1, 1990): 952–56. http://dx.doi.org/10.1515/znb-1990-0706.

Full text
Abstract:
Niobium pentabromide, NbBr5, is prepared in the orthorhombic ordered (α)-form from the elements in sealed quartz ampoules (Nb powder, Br2, l) at 973 K. The structure has been determined from single crystal data (a = 1288.8(2), b = 1869.0(3), c = 614.9(1) pm; Pnma (No. 62); Z = 8; R = 0.055). α-NbBr5_ forms dimeric Nb2Br10 molecules with d̄(Nb–Brb) = 271.5 pm, d̄(Nb–Bre) = 240.8 pm and d̄(Nb– Bra) = 246.1 pm. α-NbBr5 is a diamagnetic semiconductor with cgsχmoldia(300 K) = –72 × 10-6 cm3/mol. The band gaps of NbCl5, α-NbBr5 and NbI5 have been determined by diffuse reflection to be Eg(NbCl5) = 2.74 eV, Eg(α-NbBr5) = 1.99 eV, and Eg(NbI5) = 0.99 eV.
APA, Harvard, Vancouver, ISO, and other styles
5

Whittall, Ian R., Mark G. Humphrey, and David C. R. Hockless. "Structural Systematics of Metal Acetylide Complexes. II. X-Ray Studies of Some Nickel σ-Acetylide Complexes." Australian Journal of Chemistry 51, no. 3 (1998): 219. http://dx.doi.org/10.1071/c97082.

Full text
Abstract:
The structures of Ni(C≡CR)(PPh3)(η-C5H5) (R = Ph (1), C6H4-4-NO2 (2), 4-C6H4C6H4-4′-NO2 (3), (E)-4-C6H4CH=CHC6H4-4′-NO2 (4), 4-C6H4C≡CC6H4-4′-NO2 (5), 4-C6H4N=CHC6H4-4′-NO2 (6)) have been determined by single-crystal X-ray diffraction studies, refining by full-matrix least-squares analysis. For (1), crystals are triclinic, space group P-1, with a 10·094(2), b13·429(3), c 18·835(5) Å,α 103·24(2), β 91·50(2), γ 90·10(2)°, Z 4, 5844 unique reflections (595 parameters), converging at R 0·033 and Rw 0·024. For (2), crystals are orthorhombic, space group Pna21, with a 16·799(2), b 8·681(2), c 17·485(2) Å, Z 4, 1774 unique reflections (325 parameters), converging at R 0·031 and Rw 0·029. For (3), crystals are monoclinic, space group P 21/c, with a 11·140(3), b 18·282(4), c 15·296(2) Å, β 105·18(2)°, Z 4, 3132 unique reflections (397 parameters), converging at R 0·039 and Rw 0·024. For (4), crystals are monoclinic, space group P 21/n, with a 12·929(7), b 16·953(8), c 15·601(7) Å, β 112·55(3), Z 4, 3023 unique reflections (397 parameters), converging at R 0·039 and Rw 0·025. For (5), crystals are monoclinic, space group P 21/n, with a 12·710(5), b 16·882(3), c 15·693(4) Å, β 111·37(3)°, Z 4, 3216 unique reflections (397 parameters), converging at R 0·035 and Rw 0·030. For (6), crystals are monoclinic, space group P 21/n, with a 12·594(1), b 16·936(2), c 15·611(1) Å, β 112·476(5)°, Z 4, 3564 unique reflections (397 parameters), converging at R 0·038 and Rw 0·041. For structurally characterized 18-electron (cyclopentadienyl)nickel(II) acetylide complexes, statistically insignificant decreases in the average Ni-C(1) distance and trans influence and an increase in the average C(1)-C(2) parameter are observed on introduction of an acceptor substituent at the alkynyl ligand.
APA, Harvard, Vancouver, ISO, and other styles
6

McDonagh, Andrew M., Mark G. Humphrey, and David C. R. Hockless. "Preparation of cis- and trans-[OsCl2(Me2SO)4], and X-Ray Crystal Structures of the All-S-Bound Isomers." Australian Journal of Chemistry 51, no. 9 (1998): 807. http://dx.doi.org/10.1071/c98017.

Full text
Abstract:
Efficient syntheses of the cis and trans isomers of [OsCl2(Me2SO)4] are reported. While a structural study of thetrans isomer confirms the spectroscopically assigned all-S-bound Me2SO configuration, a crystallographic determination of the cis isomer reveals a previously unheralded all-S-bound Me2SO geometry, in contrast to the spectroscopically inferred configuration predominant in solution which has one O-bound ligand. Fortrans-[OsCl2(Me2SO)4], crystals are tetragonal, space group I 4/m, with a 9·092(2), c 11·212(3) Å, Z 2, 566 unique reflections (34 parameters), converging at R 0·026 and Rw 0·032. For cis-[OsCl2(Me2SO)4], crystals are triclinic, space group P-1, with a 8·193(2), b 8·941(3), c 13·837(3) Å, α 79·77(2), β 79·91(2), γ 65·03(2)°, Z 2, 4152 unique reflections (173 parameters), converging at R 0·021 and Rw 0·018.
APA, Harvard, Vancouver, ISO, and other styles
7

Dasari, Arvind, Joleen M. Hubbard, Cathy Eng, Heather Yeckes-Rodin, Stacey M. Ukrainskyj, Zhao Yang, William R. Schelman, Marek K. Kania, and Tanios S. Bekaii-Saab. "Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer." Journal of Clinical Oncology 40, no. 4_suppl (February 1, 2022): 93. http://dx.doi.org/10.1200/jco.2022.40.4_suppl.093.

Full text
Abstract:
93 Background: Fruquintinib (F) is a highly selective, novel, oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3. The phase (Ph) 3 FRESCO study (NCT02314819) that investigated F (5mg daily, 3 weeks (wks) on 1 wk off) showed improved median overall survival in patients (pts) with metastatic colorectal cancer (mCRC) in third line and beyond when compared to placebo (9.3 vs. 6.6 months); hazard ratio 0.65 (P < 0.001) and led to its approval in China. Methods: This is an ongoing Ph 1/1b open-label, dose escalation/expansion study conducted in the US. Here we present the preliminary safety and antitumor efficacy data from pts with refractory mCRC in Cohort (Coh) B (progressed on all standard therapies including TAS-102 [TAS] and/or regorafenib [R]) and in Coh C (did not receive TAS or R). Results: As of data cutoff on 27 July 2021, 81 mCRC pts had been treated (41 in Coh B and 40 in Coh C); median age of 57 years (range: 34─77), Caucasian (81.5%), female (44.4%), and ECOG PS 1 (59.3%). In Coh B, the median number of prior therapies was 5 (range: 3-9), 8 pts (19.5%) received R, 19 (46.3%) received TAS and 14 (34.1%) received both R and TAS. In Coh C, the median number of prior therapies was 4 (range: 1-10). Five pts remain on treatment; reasons for treatment discontinuation included: 56 pts (69.1%) due to progressive disease or death, 8 pts (9.9%) due to adverse events (AE), and 12 pts (14.8%) due to withdrawal of consent or physician decision. The median duration of F treatment was 4.4 months (range: 0.7– 20.0) in Coh B and 3.7 months (range: 0.02-14.3) in Coh C. The most frequently reported AEs of any grade in Coh B were fatigue (53.7%), proteinuria (51.2%), and hypertension (HTN; 48.8%). In Coh C the most frequently reported AEs of any grade were HTN (75.0%), proteinuria (40.0%), and myalgia (32.5%). Hand-foot syndrome (HFS) was reported in 29.3% of Coh B pts and 22.5% of Coh C pts. The disease control rate [DCR] was 68.3% in Coh B (1 partial response [PR] and 27 stable disease [SD]) and 59.5% for the 37 patients with at least one post-baseline tumor assessment in Coh C (2 PRs and 20 SDs). Conclusions: F is generally well-tolerated in heavily-pretreated pts with refractory mCRC. Evidence of antitumor activity was observed in cohorts B and C. The multi-cohort dose expansion is ongoing. F is being further investigated in refractory mCRC in a global Ph 3 study (NCT04322539). Clinical trial information: NCT03251378.
APA, Harvard, Vancouver, ISO, and other styles
8

Chow, WS, AB Hope, and JM Anderson. "Further Studies on Quantifying Photosystem II in vivo by Flash-Induced Oxygen Yield From Leaf Discs." Functional Plant Biology 18, no. 4 (1991): 397. http://dx.doi.org/10.1071/pp9910397.

Full text
Abstract:
It was shown briefly [W. S. Chow, A. B. Hope and J. M. Anderson (1989), Biochirnica et Biophysics Acta, 973, 105-8] that the oxygen evolved per flash from leaf discs, under steady-state flashing conditions and in the presence of background far-red light, gave a valid measure of the number of functional photosystem II (PS II) reaction centres. Further work on this direct and convenient method has been done to optimise conditions for making reliable measurements. It is found that, to obtain the higher estimates of [PS II], corresponding to functionality of practically all PS II reaction centres that bind herbicides, a form of 'light activation' is necessary after a prolonged dark pre-incubation. Without a sufficient number of flashes being given following a long dark incubation, the number of functional PS II reaction centres was underestimated. Provided light activation had occurred, the measured number of functional PS II reaction centres was independent of flash frequencies up to at least 40 Hz. The results strongly suggest that, in steady-state, light-limited photosynthesis, there does not exist any sub- stantial fraction of non-functional or 'slow' PS II reaction centres.
APA, Harvard, Vancouver, ISO, and other styles
9

Mendis, Shanthi, U. Samarajeewa, and R. O. Thattil. "Coconut fat and serum lipoproteins: effects of partial replacement with unsaturated fats." British Journal of Nutrition 85, no. 5 (May 2001): 583–89. http://dx.doi.org/10.1079/bjn2001331.

Full text
Abstract:
The aim of the present study was to examine the effect of reducing saturated fat in the diet, or partly replacing it with unsaturated fat, on the serum lipoprotein profile of human subjects. The study had two intervention periods, 8 weeks (phase 1) and 52 weeks (phase 2). In phase 1, total fat was reduced from 31 to 25 % energy (polyunsaturated fatty acids (PUFA):saturated fatty acids (SFA) ratio increased from 0.2 to 0.4) by reducing the quantity of coconut fat (CF) in the diet from 17.8 to 9.3 % energy intake. In phase 2, subjects were randomised to groups A and B. In group A total fat was reduced from 25 to 20 % energy (PUFA:SFA ratio increased from 0.4 to 0.7) by reducing the quantity of CF in the diet from 9.3 to 4.7 % total energy intake. In group B, the saturated fat content in the diet was similar to group A. In addition a test fat (a mixture of soyabean oil and sesame oil, PUFA:monosaturated fatty acids ratio 2) contributed 3.3 % total energy intake and total fat contributed 24 % energy intake (PUFA:SFA ratio increased from 0.7 to 1.1). At the end of phase 1, there was a 7.7 % reduction in cholesterol (95 % CI -3.6, -12.2) and 10.8 % reduction in LDL (95 % CI -4.9, -16.5) and no significant change in HDL and triacylglycerol. At the end of phase 2, the reduction in cholesterol in both groups was only about 4 % (95 % CI -12, 3.2) partly due the concomitant rise in HDL. The reduction in LDL at 52 weeks was significantly higher in group B (group A mean reduction 11 %, 95 % CI -20.1, -2.0 and group B mean reduction 16.2 % 95 % CI -23.5, -8.9). In phase 2, triacylglycerol levels showed a mean reduction of 6.5 % in group 2A and a mean increase of 8.2 % in group 2B. The reduction of saturated fat in the diet is associated with a lipoprotein profile that would be expected to reduce cardiovascular risk. The reduction of dietary saturated fat with partial replacement of unsaturated fat brings about changes in total cholesterol, HDL- and LDL-cholesterol that are associated with a lower cardiovascular risk.
APA, Harvard, Vancouver, ISO, and other styles
10

Torgashina, A., E. Sokol, J. Khvan, B. Chalcev, D. Tabakov, S. Glukhova, and O. Golovina. "OP0320 CHARACTERISTICS OF PERIPHERAL BLOOD B-CELL SUBSETS IN PATIENTS WITH SJOGREN SYNDROME." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 196.1–196. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2982.

Full text
Abstract:
Background:B-cells play a pivotal role in primary Sjogren’s syndrome (SS) pathogenesis. Recent studies have shown disturbances in the peripheral B cell populations in primary SS.Objectives:To examine В-cell subsets in peripheral blood of SS patients (pts) and to analyze the association between B-cell subsets and SS activity.Methods:Twenty active SS pts (19F/1M): median age 42 years (range) (32-54); disease duration 3 (2-10) years; ESSDAI score ≥5 in 6 pts, <5 in 14 pts), were included. SS was diagnosed based on the ACR-EULAR 2016 criteria. Twenty healthy donors composed the control group. CD19+B cells, memory B-cells (CD19+CD27+), non-switched memory B-cells (CD19+IgD+CD27+), switched memory B-cells (CD19+IgD-CD27+), naïve (CD19+IgD+CD27-), double negative (CD19+IgD-CD27-), transitional (CD19+IgD+CD10+CD38+) B-cells, plasmablasts (CD19+СD38+++IgD-CD27+), and plasma cells (CD19+СD38+) were analyzed by multicolor flow cytometry using cytometer Navios (Beckman Coulter, USA).The nonparametric Mann-Whitney test, the unpaired Student’s t test for group comparison, and the Pearson`s x2 criterion were used for statistical analysis. Data were shown as median (Me) with an interquartile range of 25 - 75 percentile. The differences were considered statistically significant when p <0.05. Statistica 10 for Windows (StatSoft Inc., USA) package was used for statistical data processing.Results:The percentages/absolute numbers of plasmablasts, plasma cells and transitional B-cells in SS were significantly higher than in healthy donors, р<0.01 for all cases (Table 1).Table 1.B-cell subsets in patients with SS, SS and MALT lymphoma and healthy donors.B-cell subsetsSSHDPt 1FN%Abs. cells/μl%Abs. cells/μl%Abs. cells/μlB lymphocyte12,8 (7,9 – 19,7)151 (95-112)8,5 (7,2-11,0)200 (100-200)4,531**plasma cells6,9 (4,2-10)12 (6-22)0,1 (0,05-0,1)0,1 (0-0,2)5,713*plasmablasts0,88 (0.37-1.8)2 (1-3)0,1 (0,1-0,2)0,2 (0,1-0,4)26,612*/**transitional B-cells5.7 (0.9-17)8 (4-32)0,1 (0-0,1)0,1 (0-0,3)00*switched cells9.1 (5.9-20.7)18 (11-29)12,8 (9,3-17,0)20 (10-40)5216**non-switched memory B-cells4.13 (2.7-5.4)7 (3-15)7,4 (3,7-11,1)10 (5-20)165**SS Sjogren’s patients; HD healthy donors, Pt 1 patient with SS and MALT lymphoma* SS and HD groups compared, р<0.01** Pt 1 and SS group comparedOne of the patients (Pt 1) was diagnosed with MALT lymphoma of the parotid salivary gland; she had a distinct B-lymphocyte subpopulations distribution, which was different from the rest of the SS group. She had the lowest percentage / absolute B lymphocyte count of all patients with SS, the highest percentage of switched cells and non-switched memory B-cells, and the highest percentages/absolute numbers of plasmablasts. For this reason, the patient was excluded from the subsequent analysis (Table 1).Patients with activity of SS by ESSDAI ≥ 5 had a significantly higher percentage of B cells (p=0.007), and significantly higher absolute B lymphocyte count of naïve cells (p=0.04) and plasmablasts (p=0.048).Conclusion:Immunophenotyping showed disturbed homeostasis of the B-cells subpopulations in our SS cohort. A significant increase in plasmablasts in SS, as well as a positive correlation of the level of plasmablasts with the SS activity and presence of lymphoma could suggest the important role of these cells in the pathogenesis of SS.Disclosure of Interests:None declared.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "973.8/092 b"

1

Thangarajh, Mathula. "B-cell-survival factors in multiple sclerosis and myasthenia gravis /." Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-097-8/.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "973.8/092 b"

1

Clark, Hine Darlene, ed. Black women in American history. Brooklyn, N.Y: Carlson Pub., 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Obama, Barack. Dreams from My Father. New York: Crown Publishing Group, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Obama, Barack. Những giấc mơ từ cha tôi. Hà Nội: Nhà xuá̂t bản Văn học, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Obama, Barack. Mai dorīmu: Baraku Obama jiden = Dreams from my father : a story of race and inheritance. Tōkyō: Daiyamondosha, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Obama, Barack. Pitā se mile sapane. Guṛagām̐va: Aravinda Kumāra Pabliśarsa, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Obama, Barack. Dreams from my father: A story of race and inheritance. New York: Kodansha International, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Obama, Barack. Oubama de meng xiang zhi lu: Yi fu zhi ming. Taibei Shi: Shi bao wen hua chu ban qi ye gu fen you xian gong si, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Obama, Barack. Dreams from my father: A story of race and inheritance. New York: Random House Large Print, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Obama, Barack. Dromen van mijn vader: Een autobiografie. Amsterdam [etc.]: Atlas, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Obama, Barack. Dromen van mijn vader: Een autobiografie. 2nd ed. Amsterdam: Atlas, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "973.8/092 b"

1

"91. Verbundenheit einer Religionsgemeinschaft i.S. von § 2 b DDR-PartG. OVG Berlin, Urteil vom 22.11.1996 (3 B 8/94)." In 1.1.–31.12.1996, 439–53. De Gruyter, 2000. http://dx.doi.org/10.1515/9783110893526-092.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Roche, Bruno, and Didier Samuel. "19 Prévention et prise en charge de la récidive virale B après transplantation hépatique." In Hépatite B, 331–46. EDP Sciences, 2020. http://dx.doi.org/10.1051/978-2-84254-223-8-022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Levrero, Massimo, Silvia Pierconti, Concetta Sava, and Letizia Cimino. "9 Virus de l’hépatite B et carcinogenèse hépatique." In Hépatite B, 139–52. EDP Sciences, 2020. http://dx.doi.org/10.1051/978-2-84254-223-8-012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pawlotsky, Jean-Michel, and Daniel Dhumeaux. "Avant-propos." In Hépatite B, xxvii—xxviii. EDP Sciences, 2020. http://dx.doi.org/10.1051/978-2-84254-223-8-002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fournier, Claire, Lucyna Cova, and Christian Trépo. "29 Hépatite chronique virale B : nouvelles perspectives thérapeutiques." In Hépatite B, 463–84. EDP Sciences, 2020. http://dx.doi.org/10.1051/978-2-84254-223-8-032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Stéphenne, Xavier, and Étienne Sokal. "26 L’hépatite B de l’enfant." In Hépatite B, 421–30. EDP Sciences, 2020. http://dx.doi.org/10.1051/978-2-84254-223-8-029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

SCHWARTZ, F., and J. BIGOT. "The Influence of the Substitution of Metallic Elements on the Thermal Stability and Magnetic Properties of Amorphous Fe–B–Si Alloys." In Rapidly Quenched Metals 6, 39–42. Elsevier, 1988. http://dx.doi.org/10.1016/b978-1-85166-973-8.50014-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Krishnamoorthy, Sivakumar, and Poongodi Thanigaivel. "Degradation of Rhodamine B Using CdS Quantum Dots Under Solar Light." In Environmental and Technological Aspects of Redox Processes, 307–22. IGI Global, 2023. http://dx.doi.org/10.4018/979-8-3693-0512-6.ch016.

Full text
Abstract:
Plate-like cadmium sulfide (CdS) quantum dots were prepared by using β-cyclodextrin as reductants. Photoluminescence and UV-Visible diffused reflectance spectroscopic techniques are used to investigate the optical property of CdS. The blue-shifted emission of CdS at 469nm than the bulk particle is observed. The calculated band gap of the CdS quantum dot is 2.62 eV showing a difference of 0.2 eV energy greater than that of bulk, indicating the quantum size effect. The synthesized quantum dot has a size in the range of 3.5nm with a zinc blend crystallite structure. The plate-like nanoclusters of CdS are inferred from SEM images. The photocatalytic efficiency of prepared CdS was tested for the degradation of rhodamine B dye using natural solar light. The effect of the weight of the catalyst, concentration of dye, pH of the solution, and reusability of the catalyst were investigated. The existence of isosbestic point observation of a high intense absorbance peak at 550nm at 300min in different matrix circumstances confirms the formation of leuco Rh B.
APA, Harvard, Vancouver, ISO, and other styles
9

"Appendice B: Physical tables and constants." In Neutron physics, 599–606. EDP Sciences, 2020. http://dx.doi.org/10.1051/978-2-7598-0324-8-022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Doepp, Manfred. "Chaotization of Human Systems by Technical Electromagnetic Fields." In Handbook of Research on Distributed Medical Informatics and E-Health, 493–99. IGI Global, 2009. http://dx.doi.org/10.4018/978-1-60566-002-8.ch035.

Full text
Abstract:
In our energy diagnostic department we noticed more and more cases with irrational stimulus-reaction- patterns and with a chaotic regulation state of the autonomous systems. We found an explanation by the ‘Switching phenomenon’. However, in addition to earlier results a new cause came up, it is the electrosmog exposure. We used three criteria to clarify the findings: A) a negative reaction on a pulsating magnetic field, B) a positive reaction on a brain synchronization procedure, and C) the frequency distribution analysis of skin resistance values approximated by a lognormal (order) or by a bell curve (chaos). A retrospective evaluation over 4 years (435 patients) was performed. Results: 1) a positive correlation between the criterium A) and a chaotic tendency in C), and 2) a significant difference between reactions before and after the synchronization procedure B). The hypothesis of an electrosmog-induced chaotization of autonomous systems becomes likely.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '973.8/092 b' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography